GEN Exclusives

More »

GEN News Highlights

More »
Jan 31, 2013

Novozymes Acquires Iogen Bio-Products

  • Novozymes acquired Iogen Bio-Products, the industrial enzyme business of Ottawa, Ontario-based Iogen for $67.3 million. The agreement gives Novozymes all commercial rights to Iogen Bio-Products’ existing product portfolio, pipeline, facilities, and expertise. The deal does not include the purchase of assets that relate to Iogen’s bioenergy process technologies.

    Iogen Bio-Products, which entered the industrial enzyme industry in 1991, produces and sells enzymes for the pulp & paper, textile, grain-processing, and animal feed industries. The company has close to 70 employees and sells more than 20 products globally.

    “Iogen Bio-Products is a good fit for Novozymes,” explained Andrew Fordyce, vp of global enzyme sales and customer solutions at Novozymes. “We get a number of products that complement our existing product portfolio and welcome a talented group of employees who are very good at developing and producing industrial enzymes.”

    Novozymes, which began its business in 1925, markets over 700 biotech products in 130 countries.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »